Sign In
Buy WGS
$53.02
-0.110 (-0.207%)
At Close: Jun 03, 2026
3 Stocks to Buy for Stellar Earnings Acceleration in November
04:05pm, Monday, 04'th Nov 2024
Stocks like Snap, GeneDx Holdings and Leonardo DRS exhibit solid earnings acceleration.
Best Momentum Stocks to Buy for November 4th
11:01am, Monday, 04'th Nov 2024
WGS, CVNA and NBBK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 4, 2024.
New Strong Buy Stocks for November 4th
06:46am, Monday, 04'th Nov 2024
CFFN, VLRS, NBBK, WGS and ISBA have been added to the Zacks Rank #1 (Strong Buy) List on November 4, 2024.
Natera And GeneDx: Outperforming Market Powered By Precision Medicines Tailwinds
06:11pm, Thursday, 31'st Oct 2024
The precision medicine market is projected to grow from $91.72 billion in 2024 to $246.3 billion by 2033, fueled by advancements in genomic technologies. In the last year, Natera, Inc. and GeneDx Hold
GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term
03:10pm, Wednesday, 30'th Oct 2024
GeneDx Holdings Corp. stock has risen by a scarcely believable >3,000% across the past year. The company provides exome sequencing products that can be used to search for and diagnose hundreds of gene
GeneDx Holdings Corp. (WGS) Q3 2024 Earnings Call Transcript
06:46pm, Tuesday, 29'th Oct 2024
GeneDx Holdings Corp. (NASDAQ:WGS ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Sabrina Dunbar - Investor Relations Katherine Stueland - President and Chief Execu
Genetic Testing Firm GeneDx Reports Narrower Q3 Loss As Revenues Surge, Lifts Annual Guidance
11:11am, Tuesday, 29'th Oct 2024
GeneDx Holdings WGS stock is trading higher on Tuesday.
GeneDx Holdings Corp. (WGS) Tops Q3 Earnings and Revenue Estimates
10:10am, Tuesday, 29'th Oct 2024
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.82 per share a year ago.
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
08:00am, Tuesday, 29'th Oct 2024
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the third quarter of 2024.
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that JAMA, the Journal of the American Medical Associa
GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists
10:00am, Monday, 21'st Oct 2024
GeneDx Holdings Corp. leverages its genomic and data science expertise to provide precise medical diagnostics, focusing on rare diseases and pediatric exome/genome testing. The company's second-quarte
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
08:30am, Tuesday, 08'th Oct 2024
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it has provided genomic newborn screenings (gNBS) for
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
04:05pm, Thursday, 03'rd Oct 2024
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx today announced it will release financial results for the third quarter of 2024 before the market opens on Tuesday, October 29, 2024.
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 27'th Sep 2024
STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS) today announced that the compensation committee of GeneDx's board of directors granted restricted stock units (“RSUs”).
GeneDx Stock Rocketed 1310% In Dramatic Turnaround Powered By DNA Analytics
08:00am, Thursday, 19'th Sep 2024
GeneDx is helping patients navigate through the "diagnostic odyssey" with DNA sequencing. The biotech stock is on its own odyssey.
